RESULTS	UBC plus BSC , compared with BSC alone , did not affect the sorafenib dose reduction or interruption rate ( 9.1 % v 11.8 % , respectively ; P = .1937 ) , response rate ( 11.1 % v 10.1 % , respectively ; P = .6674 ) , or disease control rate ( 98.8 % v 98.2 % , respectively ; P = .5350 ) at week 12 .\